Pulmonary Drugs Market
Pulmonary Drugs Market (Drug Class - Inhaled Corticosteroids (ICS), Long-Acting Beta2-Agonists (LABA), Antihistamines, Vasodilators, Short-Acting Beta2-Agonists (SABA), Anticholinergics, Combination Drugs, MAbs, Enzymes, Antibiotics, and Antileukotrienes; Application - Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, and Cystic Fibrosis; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, and E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024
- 196 Pages
Global Pulmonary Drugs Market: Snapshot
The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in 2015. Keeping aside the tremendous fall of the global pulmonary drugs market, it has been expected that the market will find growth prospects from the growing number of respiratory diseases and the fact that they are becoming the leading cause of deaths across the globe at present, especially among the aged population.
According to the Forum of International Respiratory Societies (FIRS), chronic obstructive pulmonary disease affects over 200 million people across the globe and is also one of the leading causes of death globally. On the other, over 235 million people across the globe suffer from asthma. Owing to these alarming statistics, the consumption of pulmonary drugs is likely to gain momentum, thus providing growth opportunities to the market in spite of the negative CAGR. Pulmonary drugs are also being employed for the treatment of conditions such as cystic fibrosis, respiration-related disorders, pulmonary arterial hypertension (PAH), and allergic rhinitis. The launch of many effective and innovative drugs in the global market for pulmonary drugs is also anticipated to have a positive impact on the growth of the market in the coming years.
Medical Professionals to Prefer Combination Drugs among All Others
Based on drug classes, the global market for pulmonary drugs is classified into combination drugs, anticholinergics, short acting beta2-agonists, vasodilators, antihistamines, long-acting beta2-agonists, and inhaled corticosteroids, and others such as antileukotrienes, antibiotics, enzymes, and monoclonal antibodies. Among these, the segment of combination drugs held the leading share of 27.4% in 2015 closely followed by inhaled corticosteroids with a share of 16.7% in the same year in the global pulmonary drugs market. The sales of combination drugs is likely to remain high throughout the forecast period as they are considered to be comparatively safer than the other drugs. Moreover, the advent of triple combination drugs is further projected to propel the growth of the global pulmonary drugs market over the course of the forecast period.
Advent of Middle-income Classes to Catapult Demand in Asia Pacific
Based on geography, the global market for pulmonary drugs has been classified into Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. In 2015, North America led the global pulmonary drugs market with a share of 41% with Europe closely following with a share of 32.4% in the same year. The growing use of pulmonary drugs in these regions can be attributed to the advanced healthcare infrastructure coupled with high awareness regarding treatment of pulmonary diseases. However, the rise of middle-income classes and their growing expenditure on healthcare is expected to lift Asia Pacific as a prominent region in the global market.
Some of the leading players in the market are Actelion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AstraZeneca plc, and Sunovion Pharmaceuticals Inc.
Rise in the Number of Smokers to Bolster Growth of the Pulmonary Drugs Market
Various pulmonary diseases are treated with pulmonary drugs. Medication for conditions ranging from common cold to long time healing diseases, such as COPD and asthma, includes pulmonary medication. Inhalers, oral capsules, liquids, vaccines, and other dosage formulations are amongst the pulmonary drugs available. Due to reasons such as the rising number of people who smoke, growing prevalence of COPD and various respiratory disorders, the global pulmonary drugs market is expected to rise in the coming years. Furthermore, several non-government and government programmes for research and investment in pulmonary drugs therapeutics are projected to provide substantial growth opportunities in the global pulmonary drugs market in the years to come.
High Prevalence of Respiratory Illnesses to Accelerate Demand in the Market
Pulmonary drugs can be utilized to treat a variety of illnesses that fall under the umbrella of pulmonary disorders, including pulmonary hypertension, allergic rhinitis, and pneumonia amongst others. Pulmonary drugs treat a wide range of pulmonary illnesses, which is projected to drive demand in the market in the years to come. According to the World Health Organization (WHO), most respiratory infections are treatable and preventable with the right treatment. As a result, attempts to produce safe and reliable pulmonary drugs and prescriptions have increased. Nebulizers or inhalers are used to prescribe certain respiratory medications.
Tobacco smoking and exposure to it are directly proportional to the rising prevalence of Chronic Obstructive Pulmonary Disease (COPD). According to the World Health Organization (WHO), cigarette smoking is the leading cause of COPD, accounting for almost 90% of all cases. The lifelong effects of smoking contribute to the introduction of dietary changes and medicinal therapies, such as the use of inhaled hormones, inhaled glucocorticoids, bronchodilators, and other pulmonary drugs to alleviate disease symptoms. This factor is estimated to trigger growth of the global pulmonary drugs market in the near future. Tobacco use is a leading cause of death and disease around the world. The number of cigarette smokers is stable across the globe and has not decreased in recent years. Smokers are more likely to develop respiratory conditions like asthma and COPD.
Global Pulmonary Drugs Market: Snapshot
This report on pulmonary drugs studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pulmonary drugs market with respect to the leading market segments based on major products, key applications, distribution channels, and geographies.
Global Pulmonary Drugs Market: Segmentation
The global pulmonary drugs market has been studied based on major drug classes, application segments, major distribution channels, and regional as well as national markets. Based on drug classes, the global market has been categorized into eight major segments: Inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), antihistamines, vasodilators, short-acting beta2-agonists (SABA), anticholinergics, combination drugs, and others. Based on application, the global market has been categorized into five segments: Asthma & COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others. Based on distribution channels, the global market has been categorized into four key segments: hospital pharmacies, retail pharmacies, drug stores, and e-commerce.
The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year.
Global Pulmonary Drugs Market: Scope
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pulmonary drugs market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products/applications/distribution channels/geographies. The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the pulmonary drugs market report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global pulmonary drugs market.
Global Pulmonary Drugs Market: Geographical Outlook
Geographically, the pulmonary drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Each regional market for pulmonary drugs market has been further categorized into major product, application, and end-user segments considered within the scope of the study. Key country (U.S., Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year.
Key Players Mentioned in the Report are:
The report also profiles key players operating in the pulmonary drugs market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include AstraZeneca plc, Novartis AG, F. Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals, Inc. and others
The global pulmonary drugs market has been segmented as follows:
Global Pulmonary Drugs Market Revenue, by Drug Class
- Inhaled Corticosteroids (ICS)
- Long-Acting Beta2-Agonists (LABA)
- Short-Acting Beta2-Agonists (SABA)
- Combination Drugs
- Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
Global Pulmonary Drugs Market Revenue, by Application
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
Global Pulmonary Drugs Market Revenue, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
Global Pulmonary Drugs Market Revenue, by Geography
- North America
- Rest of Europe
- Asia Pacific
- New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa